Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DC-Ova
- Development stage
- Phase 1
- Lead developer
- University of Pennsylvania
- Modality
- Vaccines & Immunotherapeutics, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Administration
- Intravenous, Subcutaneous, Intradermal, Intranodal, Intratumoral
01
Overview
DC-Ova is an investigational immunostimulant drug developed by the University of Pennsylvania. It is a dendritic cell-based vaccine in which dendritic cells (DCs) are pulsed or loaded with ovalbumin (OVA), a model antigen, to stimulate antigen-specific immune responses. The primary mechanism involves presenting OVA-derived peptides to T cells, thereby priming and activating both CD4+ and CD8+ T cell responses against OVA-expressing targets. This approach has been widely used in preclinical models for cancer immunotherapy research and for studying immune mechanisms in diseases such as asthma. The vaccine leverages the potent antigen-presenting capabilities of dendritic cells to induce robust adaptive immunity, making it a valuable tool for both therapeutic development and basic immunology research[1][4].
- Brand names
- OVA peptide-pulsed dendritic cell vaccine
- Other names
- OVA-DC vaccineovalbumin peptide-pulsed dendritic cell vaccine
02
Targets
OVA-specific TCR (Ovalbumin-specific T-cell receptor)
Beyond the preview
Go deeper on DC-Ova.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DC-Ova.